CRP and non-small cell lung carcinoma: In the first of these, Oya et al. reported that elevations in serum CRP of ≥10 micrograms/milliliter (μg/mL), recorded in 60 /124 patients with advanced NSCLC prior to administration of nivolumab, were associated with significant reductions in median PFS (1.8 vs. 4.0 months, P < 0.01, for patients with high and low CRP values, respectively) and OS (7.8 months vs. not reached, P < 0.01).